Paul M. Palevsky

Paul M. Palevsky

Auto-generated profile, based on publicly available information

Paul M. Palevsky

Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2015 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
EHEric Hoste
Eric Hoste
SBSean M. Bagshaw
Sean M. Bagshaw
RBRinaldo Bellomo
Rinaldo Bellomo
CCCynthia M. Cely
Cynthia M. Cely
RCRoos Colman
Roos Colman
JKJohn A. Kellum
John A. Kellum

22 August 2018 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
EHEric Hoste
Eric Hoste
JKJohn A. Kellum
John A. Kellum
NSNicholas M Selby
Nicholas M Selby
AZAlexander Zarbock
Alexander Zarbock
PPPaul M. Palevsky
Paul M. Palevsky
LCLakhmir S. Chawla
Lakhmir S. Chawla

14 November 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LFLinda F. Fried
Linda F. Fried
NENicholas Emanuele
Nicholas Emanuele
JZJane H. Zhang
Jane H. Zhang
MBMary Brophy
Mary Brophy
TCTodd A. Conner
Todd A. Conner
PGPeter Guarino
Peter Guarino
Combination therapy with angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain.

19 July 2023 in Nature
Verified
Journal Article
Open access
PDF file
BLBlue B. Lake
Blue B. Lake
RMRajasree Menon
Rajasree Menon
SWSeth Winfree
Seth Winfree
QHQiwen Hu
Qiwen Hu
RFRicardo Melo Ferreira
Ricardo Melo Ferreira
SJSanjay Jain
Sanjay Jain
Understanding kidney disease relies on defining the complexity of cell types and states, their associated molecular profiles and interactions within tissue neighbourhoods1. Here we applied multiple single-cell and single-nucleus assays (>400,000 nuclei or cells) and spatial imaging technologies to a broad spectrum of healthy reference kidneys (45 donors) and diseased kidneys (48 patients). This has provided a high-resolution cellular atlas of 51 main cell types, which include rare and previously undescribed cell populations. The multi-omic approach provides detailed transcriptomic profiles, regulatory factors and spatial localizations spanning the entire kidney. We also define 28 cellular states across nephron segments and interstitium that were altered in kidney injury, encompassing cycling, adaptive (successful or maladaptive repair), transitioning and degenerative states. Molecular signatures permitted the localization of these states within injury neighbourhoods using spatial transcriptomics, while large-scale 3D imaging analysis (around 1.2 million neighbourhoods) provided corresponding linkages to active immune responses. These analyses defined biological pathways that are relevant to injury time-course and niches, including signatures underlying epithelial repair that predicted maladaptive states associated with a decline in kidney function. This integrated multimodal spatial cell atlas of healthy and diseased human kidneys represents a comprehensive benchmark of cellular states, neighbourhoods, outcome-associated signatures and publicly available interactive visualizations.

1 May 2013 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PPPaul M. Palevsky
Paul M. Palevsky
KLKathleen D. Liu
Kathleen D. Liu
PBPatrick D. Brophy
Patrick D. Brophy
LCLakhmir S. Chawla
Lakhmir S. Chawla
CPChirag R. Parikh
Chirag R. Parikh
SWSteven D. Weisbord
Steven D. Weisbord

1 March 2019 in Chest
Verified
Journal Article
Closed access
STSrijan Tandukar
Srijan Tandukar
PPPaul M. Palevsky
Paul M. Palevsky